{
    "nct_id": "NCT03260894",
    "official_title": "A Randomized, Open-Label, Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care (Sunitinib or Pazopanib) as First-Line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma (mRCC) (KEYNOTE-679/ECHO-302)",
    "inclusion_criteria": "* Histologic confirmation of locally advanced or metastatic RCC with a clear-cell component with or without sarcomatoid features.\n* Must not have received any prior systemic therapy for their mRCC.\n* Measurable disease based on RECIST v1.1.\n* Archival tumor tissue sample or newly obtained core or excisional biopsy of a tumor lesion as required.\n* Karnofsky performance status â‰¥ 70%.\n* Adequate organ function per protocol-defined criteria.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Use of protocol-defined prior/concomitant therapy.\n* Currently receiving or has received an investigational treatment as part of a study of an investigational agent or has used an investigational device within 4 weeks before randomization.\n* History of severe hypersensitivity reaction to study treatments or their excipients.\n* Active autoimmune disease that has required systemic treatment in past 2 years.\n* Known additional malignancy that has progressed or has required active treatment in the last 3 years.\n* Known active central nervous system metastases and/or carcinomatous meningitis.\n* History of (noninfectious) pneumonitis that required steroids or current pneumonitis.\n* History or presence of an abnormal electrocardiogram that, in the investigator's opinion, is clinically meaningful.\n* Significant cardiac event within 12 months before Cycle 1 Day 1.",
    "miscellaneous_criteria": ""
}